Hubert Birner

Managing Partner at TVM Capital GmbH

Hubert Birner

Hubert Birner

Managing Partner at TVM Capital GmbH

Overview
Career Highlights

TVM Capital GmbH
TVM Life Science Management, Inc.
TVM Life Science Management GmbH

RelSci Relationships

2549

Number of Boards

25

Birthday

1967

Age

54

Relationships
RelSci Relationships are individuals Hubert Birner likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chairman & Chief Executive Officer at TVM Capital Healthcare Partners Ltd.

Relationship likelihood: Strong

Managing Partner-Finance at TVM Capital GmbH

Relationship likelihood: Strong

Director at Waters Corp.

Relationship likelihood: Strong

Managing Partner, Montreal at TVM Life Science Management, Inc.

Relationship likelihood: Strong

Managing General Partner at NGN Capital LLC

Relationship likelihood: Strong

General Partner at TVM Capital GmbH

Relationship likelihood: Strong

Founder at Wellington Partners GmbH

Relationship likelihood: Strong

General Partner at TVM Capital GmbH

Relationship likelihood: Strong

Chairman & President at Alpex Pharma SA

Relationship likelihood: Strong

Chief Executive Officer & Non-Executive Director at NOXXON Pharma AG

Relationship likelihood: Strong

Paths to Hubert Birner
Potential Connections via
Relationship Science
You
Hubert Birner
Managing Partner at TVM Capital GmbH
Education
Ph.D. in Biochemistry, summa cum laude

Ludwig-Maximilians-Universität München is a premier academic and research institutions.

MBA

Harvard Business School (HBS) is the graduate business school of Harvard University in Boston, Massachusetts, United States. The school offers a large full-time MBA program, doctoral programs, and many executive education programs. It owns Harvard Business School Publishing, which publishes business books, leadership articles, online management tools for corporate learning, case studies, and the monthly Harvard Business Review.

Career History
Managing Partner
2000 - Current

TVMC is a private equity investment manager focused on the technology and life sciences industries. The firm aims to foster the development of international science-based businesses in Europe, the US and Asia. They invest primarily in early-stage businesses, complemented with investments in later-stage companies in Europe and the US.TVMC favors companies with experienced management, a balanced functional team and international representation. They invest in science-based industries including information technology, communications and life sciences. The firm's investments in the life sciences sector focus on the discovery, development and delivery of innovative drugs, as well as on related technologies. TVMC's investments in technology focus on building global companies supported by international venture capital syndicates. The firm has invested in semiconductors, telecommunications, business software, energy storage, energy efficiency and water treatment.In the US, TVMC co-invests in revenue-stage companies and helps them expand internationally, while in Europe the firm aims to lead or co-lead several rounds of venture capital financing. They promote the growth of their portfolio companies through management team enhancement, syndicated financing as well as strategic repositioning and partnerships. Exit strategies include listing on European and US stock exchanges.

Managing Partner, Montreal & Munich
Current
General Partner, Director
Current

Horizon Therapeutics Schweiz GmbH is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company was originally founded in 2004 as a spin-out of Merck KGaA and is headquartered in Reinach, Switzerland.

Boards & Committees
Director
Current

SpePharm AG acquires, registers, and markets medical value medicines for the hospital sector. Its brands include Dantrium IV, Dantrium, Dantamacrin, Lymphoseek and Mugard. The company was founded in 2012 and is headquartered in Luzern, Switzerland.

Director
2014 - 2015

Vivoryon Therapeutics NV is a biopharmaceutical company, which engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its product pipeline includes PQ912, PBD-C06, and PQ1565. The company was founded by Hans-Ulrich Demuth and Konrad Glund on July 25, 1997 and is headquartered in Halle, Germany.

Independent Director
2010 - Prior

Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises of medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Hubert Birner. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Hubert Birner's profile does not indicate a business or promotional relationship of any kind between RelSci and Hubert Birner.